Demographic and psychological predictors of community pharmacists’ cancer-related conversations with patients: a cross-sectional analysis and survey study

Robert S. Kerrison1*, Anna Robinson2, Hanna Skrobanski1,3, Ghalia Kayal4, Aradhna Kaushal4, Charlotte Ide-Walters5,6, Adam Todd2, Andrew Husband2, Shivali Lakhani7, Marsha Alter7, Christian von Wagner4 and Lindsay MacDonald5

Abstract

Background: There is increasing interest in the role of community pharmacy in the early diagnosis and prevention of cancer. This study set out to examine how often community pharmacists (CPs) encourage patients to spot or respond to potential signs and symptoms of cancer, and how often they help people to make an informed decision about taking part in bowel cancer screening.

Methods: Data from 400 UK CPs, who completed the 2018 Cancer Research UK Healthcare Professional Tracker survey, were analysed. The primary outcomes were: ‘how often CPs encourage patients to spot or respond to potential signs and symptoms of cancer’ and ‘how often CPs encourage eligible people to make an informed decision to participate in bowel cancer screening’. Associations between behaviours and demographic and psychological variables (Capability, Opportunity and Motivation) were assessed using multivariate logistic regression.

Results: Most (n = 331, 82.8%) CPs reported occasionally, frequently or always encouraging patients to spot or respond to potential signs and symptoms of cancer, while only half (n = 203, 50.8%) reported occasionally, frequently or always helping people make an informed decision to participate in bowel cancer screening. Female sex (aOR: 3.20, 95%CI: 1.51, 6.81; p < 0.01) and increased Opportunity (aOR: 1.72, 95%CI: 1.12, 2.64; p < 0.05) and Motivation (aOR: 1.76, 95%CI: 1.37, 2.27; p < 0.001) were associated with encouraging patients to spot or respond to potential signs and symptoms of cancer; all three psychological variables were associated with helping people to make an informed decision to participate in bowel cancer screening (Capability: aOR: 1.39, 95%CI: 1.26, 1.52, p < 0.001; Opportunity: aOR: 1.44, 95%CI: 1.11, 1.87; p < 0.01; Motivation: aOR: 1.45, 95%CI: 1.05, 2.00; p < 0.05).

Conclusions: Most CPs encourage patients to spot or respond to potential cancer symptoms, while only half help them make an informed decision to participate in bowel cancer screening. A multifaceted approach, targeting multiple COM-B components, is required to change these behaviours.

Keywords: Community Pharmacy, Early Diagnosis, Prevention, Screening, Cancer, Bowel Cancer

Background

Cancer is a leading cause of mortality in the United Kingdom [1]. One and five year survival rates are low compared with countries with comparable healthcare
systems (e.g. Australia) [2]. Recognising the signs and symptoms of cancer can play an important part in ensuring early disease diagnosis, which, in turn, can improve survival outcomes for patients [3, 4]. However, most people living in the UK fail to recognise signs and symptoms of cancer, and this has been identified as a major contributor to delayed help-seeking by patients [3, 5, 6].

Screening can also help to detect cancer early, by testing for cancerous or precancerous changes before symptoms develop. However, as with many services, the benefits of screening are limited to those who accept and are eligible to take part in the screening programme. At present, both breast and cervical screening achieve uptake of >75.0% across the UK population (in 2018, uptake of breast and cervical screening was 81.8% and 76.4%, respectively). By comparison, uptake of bowel cancer screening is lower, with <60.0% of invitees participating when invited [7].

Increased focus has subsequently been placed on promoting the uptake of bowel cancer screening (also termed ‘colorectal cancer screening’, or ‘CRC screening’), as well as raising awareness of the signs and symptoms of cancer more generally [8]. One healthcare setting that is increasingly helping to deliver these objectives is community pharmacy [9]. Community pharmacy is thought to be particularly well situated to delivering these objectives for two key reasons: first, they are highly accessible to the general population (approximately 90.0% of people in England live within a 20-min walk of a community pharmacy [10]) and, second, they tend to employ people from the local community and are reflective of the local population (hence, people are more comfortable talking to the community pharmacy team about certain conditions) [11]. Community pharmacy, consequently, has the potential to address both cultural and linguistic barriers to information provision, as well as addressing the challenges of healthcare accessibility in deprived areas [10]. The extent to which community pharmacists (CPs) engage with patients in relation to cancer symptoms and bowel cancer screening, however, is unknown.

The aim of the present study was to better understand the working behaviours of CPs in relation to the early diagnosis of cancer. Specifically, this study set out to assess the current practices of CPs in helping patients to: (i) spot and/or respond to potential signs and symptoms of cancer and, (ii) make an informed decision about participating in CRC screening. A secondary aim was to establish the demographic and psychological predictors of these behaviours, to inform the development of future interventions.

### Methods

#### Design

Cross-sectional analysis was performed on questionnaire data collected from the 2018 Cancer Research UK Healthcare Professional Tracker Survey (HPTS).

#### Data Source

The HPTS is an online survey of UK healthcare professionals, which aims to assess their knowledge, behaviour and beliefs regarding the prevention, early diagnosis and screening of cancer. It was first commissioned in 2010, by a consortium of eight charities (including Cancer Research UK); however, in 2013, Cancer Research UK began commissioning the HPTS independently. The data were collected by Dynata UK’s Healthcare Professional Panel (Dynata, formerly known as ‘Research Now’, are a health market research agency who conduct online sampling and digital data collection) [12]. Consistently surveyed healthcare professionals include Practice Nurses and General Practitioners (GPs), with CPs and Dentists surveyed during intermittent rounds of the survey. Questions cover a variety of topics, including: 1) health professionals’ knowledge of cancer prevention, warning signs, and available screening programmes; 2) health professionals’ practices (e.g. discussions with patients) relating to the prevention, early diagnosis and screening of cancer and, 3) Health Professionals’ beliefs (e.g. perceived confidence, skills and role) about their contribution to cancer prevention, early diagnosis and screening (Appendix 1).

#### Participants

Participants were CPs from across the UK (England, Scotland, Wales and Northern Ireland), who had taken part in the 2018 wave of the HPTS (the most recent wave of the HPTS that included CPs).

#### Recruitment

For the 2018 wave, specifically, Pharmacists who self-identify as ‘Community Pharmacists,’ were invited by postal invitations (by Dynata), which provided a link to the online survey. The addresses of self-identified CPs were collected by Dynata UK’s Healthcare Professional Tracker Panel (Dynata, formerly known as ‘Research Now’ , are a health market research agency who conduct online sampling and digital data collection) [12]. Consistently surveyed healthcare professionals include Practice Nurses and General Practitioners (GPs), with CPs and Dentists surveyed during intermittent rounds of the survey. Questions cover a variety of topics, including: 1) health professionals’ knowledge of cancer prevention, warning signs, and available screening programmes; 2) health professionals’ practices (e.g. discussions with patients) relating to the prevention, early diagnosis and screening of cancer and, 3) Health Professionals’ beliefs (e.g. perceived confidence, skills and role) about their contribution to cancer prevention, early diagnosis and screening (Appendix 1).

The HPTS was referred to as a ‘Community Pharmacy’ study in the postal invitation, so that its association with Cancer Research UK was not mentioned, to avoid the survey being suggestive in any way (i.e. to reduce bias...
towards those with greater interest in cancer). Dynata state that approximately 8,000 CPs were sent a postal invitation to take part in the 2018 survey, and that the survey took 10–15 min to complete. CPs were paid £17 (by Dynata) for their participation in the survey.

Measures

Outcome measures
This analysis aimed to understand the extent to which CPs help their patients with issues relating to cancer symptoms and cancer screening. The questionnaire contained two relevant items of interest: 1) encouraging people to spot and/or respond to potential signs and symptoms of cancer ('In your role as a healthcare professional, how often do you encourage people to spot and/or respond to potential signs and symptoms of cancer?') and 2) Helping people make an informed decision about participating in CRC screening ('In your role as a healthcare professional, how often do you help people make an informed decision about participating in screening for bowel cancer?'). Responses for both outcomes were measured using a five-point Likert scale, with response options: 'never', 'rarely', 'occasionally', 'frequently' and 'always' (Appendix 1). As certain response options were selected by only a small number of respondents, participant responses have been dichotomised as 'never/rarely' and 'occasionally/frequently/always' for the purposes of the analysis.

Demographic characteristics
Due to the exploratory nature of this research, all demographic variables measured by the survey were selected for use. These included: sex (response options: 'male', 'female'), ethnicity (response options: 'White British/Irish/Other', 'Asian/Asian British', 'Black/Black British', 'Chinese or other east and southeast Asian', 'Mixed', 'Any other mixed', 'Other', 'Wouder rather not say'), geographical region (response options: 'Channel Islands', 'East of England', 'East Midlands', 'London', 'North East', 'North West', 'Northern Ireland', 'Scotland', 'South East', 'South West', 'Wales', 'West Midlands', 'Yorkshire', 'Not on the map'), age (continuous) and number of years qualified (continuous).

As certain response options were selected by only a small number of respondents, responses for 'ethnicity' were categorised as: 'White British/Irish/Other' (White British/Irish/Other) and 'Any other ethnic group' (Asian / Asian British + Black/Black British + Chinese or other east and southeast Asian + Mixed + Any other mixed + Other [no one stated 'would rather not say']), while 'geographic region' was categorised as 'England' (London, West, East Midlands, Northwest, East, Northeast, Yorkshire, Southeast and Southwest) and 'The devolved nations' (Scotland, Wales and Northern Ireland [no one stated 'not on the map']).

Psychological variables
Respondents were asked to indicate their agreement (on a five-point Likert scale, ranging from 'Strongly disagree' [1], to 'Strongly agree' [5]) with seven items relating to how often they encourage people to spot and/or respond to potential signs and symptoms of cancer:

1. It's part of my role to spot potential signs and symptoms of cancer
2. I feel I have the knowledge to spot potential signs and symptoms of cancer
3. I feel I have the time to discuss and carry out necessary examinations to spot potential signs and symptoms of cancer
4. I feel there is enough training about how to spot potential signs and symptoms of cancer
5. I feel confident in making appropriate referrals for potential signs and symptoms of cancer
6. I believe I can positively influence my patients’ cancer outcomes
7. I feel there is enough training about how to talk to patients/customers about cancer in general

Similarly, respondents were asked to rate their agreement (again, on a five-point Likert scale with the same response options as above) with six items relating to how often they help people to make an informed decision about taking part in bowel cancer screening:

1. I feel confident helping people make an informed decision about participating in Bowel cancer screening
2. I would like to take a more active role in helping people make an informed decision about participating in Bowel cancer screening
3. I feel I have the knowledge to help people make an informed decision about participating in Bowel cancer screening
4. I feel I have the time to help people make an informed decision about participating in bowel cancer screening
5. I feel I have the skills to help people make an informed decision about participating in bowel cancer screening
6. There is enough training available about how I can counsel people about the benefits and risks of participating in bowel cancer screening
**Mapping psychological items onto the COM-B (Capability, Opportunity, Motivation and Behaviour) model**

In order to assess the current practices of CPs and aid interpretation of the data, psychological variables were mapped onto the Capability, Opportunity, Motivation, Behaviour (COM-B) model by Michie et al. (Table 1 and 2) [14, 15]. The COM-B model stipulates that behaviours are the result of three-way interactions between capability (both physical and psychological), opportunity (both social and physical) and motivation (both reflective and automatic) components (as demonstrated in Fig. 1). The COM-B model lies at the centre of the behaviour change wheel, a framework for developing behavioural interventions, and can be used as a starting point for intervention development [16]. By mapping psychological items to the COM-B model, we hope to identify areas of focus to best support CP behaviour change using a theory-based approach.

The process of mapping psychological variables onto the COM-B model was achieved through detailed discussion between the authors, using the definitions for Capability, Opportunity and Motivation as described by Michie et al. [14, 15]. Items were first coded by CvW, whose coding was reviewed and agreed by RK and HS. Factor analysis with principal component factor analysis and Oblimin rotation was then performed to test whether there was a high correlation between the variables as grouped by the researchers (the loading criterion was set at 0.40 and above) [18]. The results confirmed high correlation between the items within the ascribed categories (Appendix 2); scales were subsequently computed for each of the COM-B components by calculating the sum of their scores (values were assigned to the following responses: Strongly disagree = 1; Disagree = 2; Neither agree nor disagree = 3; Agree = 4; Strongly agree = 5). For the ‘encourage people to spot and/or respond to potential signs and symptoms of cancer’ outcome-specific variables, this led to the creation of a multi-item Capability scale ranging from 4–20, a single-item Opportunity scale ranging from 1–5, and a two-item Motivation scale ranging from 2–10 (Table 1). For the ‘help people to make an informed decision about participating in screening for bowel cancer’ outcome-specific variables, the process led to the creation of a multi-item Capability scale ranging from 4–20, a single-item Opportunity scale ranging from 1–5, and a two-item Motivation scale ranging from 2–10 (Table 1). For the ‘help people to make an informed decision about participating in screening for bowel cancer’ outcome-specific variables, the process led to the creation of a multi-item Capability scale ranging from 4–20, a single-item Opportunity scale ranging from 1–5, and a two-item Motivation scale ranging from 2–10 (Table 1).

### Table 1

| Capability                                                                 | Opportunity                                                                 | Motivation                                                                 |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| ‘I feel there is enough training about how to talk to patients/ customers about cancer in general’ | ‘I feel I have the time to discuss and carry out necessary examinations to spot potential signs and symptoms of cancer’ | ‘It’s part of my role to spot potential signs and symptoms of cancer’ |
| ‘I feel confident in making appropriate referrals for potential signs and symptoms of cancer’ | ‘I feel I have the knowledge to spot potential signs and symptoms of cancer’ | ‘I believe I can positively influence my patients’ cancer outcomes’ |

### Table 2

| Capability                                                                 | Opportunity                                                                 | Motivation                                                                 |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| ‘I feel I have the skills to help people make an informed decision about participating in bowel cancer screening’ | ‘I feel I have the knowledge to help people make an informed decision about participating in Bowel cancer screening’ | ‘I feel I have the knowledge to help people make an informed decision about participating in Bowel cancer screening’ |
| ‘I feel confident helping people make an informed decision about participating in Bowel cancer screening’ | ‘There is enough training available about how I can counsel people about the benefits and risks of participating in bowel cancer screening’ | ‘I feel I have the time to help people make an informed decision about participating in bowel cancer screening’ |
| ‘There is enough training available about how I can counsel people about the benefits and risks of participating in bowel cancer screening’ | | |
ranging from 1–5, and a single-item Motivation scale ranging from 1–5 (Table 2).

Missing data
As the response format for all survey items was forced choice (i.e. respondents could not progress through the questionnaire until a response option for each question had been selected), there were no missing data for any of the variables.

Quality control
Prior to analysis by the research team, the following checks were carried out by Dynata:

1. checking of the completeness/appropriateness of open-ended responses [19]: data was reviewed to ensure that open-ended responses were logical (e.g. whether respondent’s ‘number of years qualified’ was accurate in regard to their age), and there were no vague or incomplete answers;
2. identification of ‘speeders’ [16]: data from respondents who spent less than a third of the median length of survey time were removed. This ensured the removal of respondents who, it was felt by Dynata, had completed the survey too quickly to have read or understood the survey items efficiently.

These quality checks were carried out to ensure the removal of any respondents who appeared to be rushing, or not paying sufficient attention to the survey items; an approach previously described by Conrad et al., (2017). Said checks resulted in the removal of seven respondents.

Patient and public involvement
There was no patient and public involvement in this study.

Statistical analyses
Descriptive statistics were used to describe the demographic characteristics of the sample. Binary logistic regression was used to test for multivariate associations between co-variates (both demographic and psychological) and how often community pharmacists (i) encourage patients to spot or respond to potential signs and symptoms of cancer and, (ii) help patients to make an informed decision about participating in CRC screening. Ordinal regression was also performed to test for these associations, to test whether associations were present,
before dichotomising the data. The amount of variance explained by each model was assessed using the Nagelkerke $R^2$ statistic. All analyses were performed using SPSS (version 25).

**Results**

**Factor analysis of COM-B items for encouraging patients to spot and respond to potential warning signs of cancer**

After Oblimin rotation, a total of 7 items loaded significantly onto 3 factors (labelled ‘Capability’, ‘Opportunity’ and ‘Motivation’) for ‘Encouraging patients to spot and respond to potential warning signs of cancer’. Collectively, the three factors explained a total of 79.72% of the variance.

The results of the analysis are shown in Appendix 2A. The Capability items were loaded together (these four items loaded onto the first factor and ranged from 0.67 to 0.90) and accounted for 59.45% of the variance. In addition, the Motivation items loaded together (these two items loaded onto the third factor and ranged from 0.90 and 0.71) and accounted for a further 12.45% of the variance. Finally, the one item for Opportunity loaded separately (with a loading value of 0.93), and accounted for an additional 7.76% of the variance. Zero items were deleted because of a loading lower than 0.40.

**Factor analysis of COM-B items for encouraging patients to spot and respond to potential warning signs of cancer**

After Oblimin rotation, a total of 6 items loaded significantly onto 3 factors (labelled ‘Capability’, ‘Opportunity’ and ‘Motivation’) for ‘Helping people make an informed decision about bowel cancer screening’. Collectively, the three factors explained a total of 82.41% of the variance.

The results of the analysis are shown in Appendix 2B. The Capability items were loaded together (these four items loaded onto the first factor and ranged from 0.79 to 0.89) and accounted for 54.79% of the variance. The Motivation and Opportunity items loaded separately (with loading values of 0.99 and 0.98, respectively) and accounted for a further 16.82% and 10.80% of the variance, respectively. Zero items were deleted because of a loading lower than 0.40.

**Sample characteristics**

|                      | n (%)   |
|----------------------|---------|
| **Sex**              |         |
| Male                 | 271 (67.8) |
| Female               | 129 (32.2) |
| **Ethnicity**        |         |
| White British/Irish/Other | 208 (52.0) |
| Any other ethnic group | 43 (48.0)  |
| **Region**           |         |
| England              | 337 (84.2) |
| Devolved nations of the UK: Northern Ireland, Scotland, Wales | 63 (15.8) |
| **Number of years qualified, Mean (SD)** |         |
| Number of years (Continuous) | 19.84 (10.6) |
| Number of years (SD)  | 43.30 (10.0) |

**Analysis**

Encourage people to spot and/or respond to potential signs and symptoms of cancer

Table 4 shows the percentage of CPs who reported helping patients to spot and/or respond to potential signs and symptoms of cancer. The majority ($n=331$, 82.8%) reported encouraging patients occasionally, frequently or always; while only 1 in 5 ($n=69$, 17.3%) reported never or rarely encouraging patients. The distribution of the responses, prior to being dichotomised, is demonstrated in Fig. 2.

The logistic regression explained 34.0% of the variance ($R^2 = 0.34$; Table 4). Female sex was the only demographic factor associated with being more likely to occasionally, frequently or always encourage patients (89.1% of female CPs responded ‘occasionally, frequently or always’, compared with 79.1% of male CPs: adjusted odds ratio [aOR]: 3.20, 95%CI: 1.51, 6.81; $p<0.01$). Of the COM-B variables, increased Opportunity and increased Motivation were both associated with occasionally, frequently or always encouraging patients to spot and/or respond to potential signs and symptoms of cancer (the mean Opportunity scores were 2.80 for those who responded ‘occasionally, frequently or always’ and 2.00 for those who responded ‘never/rarely’: aOR: 1.72, 95%CI: 1.12, 2.64; $p<0.05$; the mean Motivation scores were 5.7 and 3.7 for those who responded ‘occasionally, frequently or always’ and ‘never/rarely’, respectively: aOR: 1.76, 95%CI: 1.37,
## Table 4  Demographic and psychological predictors of encouraging people to spot and/or respond to potential signs and symptoms of cancer

| Demographic factors          | Never/Rarely (n = 69) | Occasionally/Frequently/Always (n = 331) | Adjusted OR (95%CI) |
|-----------------------------|-----------------------|------------------------------------------|---------------------|
| **Sex** n (%)               |                       |                                          |                     |
| Male                        | 55 (20.3)             | 216 (79.7)                               | 1.00                |
| Female                      | 14 (10.9)             | 115 (89.1)                               | **3.20 (1.51, 6.81)** |
| **Ethnicity, n (%)**        |                       |                                          |                     |
| White British/Irish/Other   | 27 (13.0)             | 181 (87.0)                               | 1.00                |
| Other + Black + Chinese     | 42 (21.9)             | 150 (78.1)                               | 0.80 (0.40, 1.58)   |
| **Region, n (%)**           |                       |                                          |                     |
| England                     | 59 (17.5)             | 278 (82.5)                               | 1.00                |
| Devolved nations of the UK. | 10 (15.9)             | 53 (84.1)                                | 1.10 (0.43, 2.82)   |
| **Age, Mean (SD)**          |                       |                                          |                     |
| Years (Continuous)          | 42.2 (9.9)            | 43.5 (10.0)                              | 0.96 (0.86, 1.06)   |
| **Number of years qualified, Mean (SD)** | | |                     |
| Years (Continuous)          | 18.2 (10.1)           | 20.2 (10.7)                              | 1.08 (0.98, 1.20)   |
| **COM-B factors, Mean (SD)**|                       |                                          |                     |
| Capability (4 – 20)         | 9.2 (3.2)             | 12.1 (3.2)                               | 1.06 (0.92, 1.21)   |
| Opportunity (1 – 5)         | 2.0 (0.9)             | 2.8 (1.4)                                | **1.72 (1.12, 2.64)** |
| Motivation (2 – 10)         | 5.7 (1.7)             | 2.6 (1.1)                                | **1.76 (1.37, 2.27)** |

\[ R^2 = 0.34 \]

*P < 0.05
**P < 0.005
***P < 0.001

![Fig. 2](image-url)  Distribution of responses to ‘encouraging people to spot cancer symptoms’ and ‘helping people make an informed decision about participating in screening for bowel cancer’
The results were the same for the ordinal regression model, which confirmed that female sex, increased Opportunity and increased Motivation were all predictors of encouraging patients to spot or respond to potential signs and symptoms of cancer (in the ordinal regression, 35.0% of the variance was explained: $R^2 = 0.35$; Appendix 4a).

**Help people make an informed decision about participating in screening for bowel cancer**

Table 5 shows the percentage of CPs who reported helping people make an informed decision about participating in screening for bowel cancer. Just over half ($n = 203, 50.8\%$) reported encouraging patients occasionally, frequently, or always, while slightly less than half ($n = 197, 49.2\%$) reported never or rarely encouraging patients (Table 5). The distribution of the responses, prior to being dichotomised, is demonstrated in Fig. 2.

The logistic regression explained 41.0% of the variance ($R^2 = 0.41$; Table 5). There were no demographic differences between CPs who never/rarely or occasionally/frequently always help people make an informed decision about participating in screening for bowel cancer. All three COM-B variables were associated with helping people make an informed decision about participating in bowel cancer screening (the mean Capability scores were 13.7 and 10.0 for those who responded ‘occasionally, frequently always’ and ‘never/rarely’, respectively: aOR: 1.39, 95%CIs: 1.26, 1.52, $p < 0.001$; the mean Opportunity scores were 3.2 and 2.4 for those who responded ‘occasionally, frequently always’ and ‘never/rarely’, respectively: aOR: 1.44, 95%CIs: 1.05, 2.00; $p < 0.05$; Table 5). The results were the same for the ordinal regression model, which confirmed increased Capability, increased Opportunity and increased Motivation were all predictors of helping people make a decision about participating in screening for bowel cancer occasionally, frequently or always (in the ordinal regression, 35.0% of the variance was explained: $R^2 = 0.41$; Appendix 4b).

### Table 5  Demographic and psychological predictors of helping people make an informed decision about participating in screening for Bowel Cancer?

| Demographic factors | Never/Rarely ($n = 197$) | Occasionally/Frequently/Always ($n = 203$) | Adjusted OR (95%CI) |
|---------------------|---------------------------|----------------------------------------------|---------------------|
| **Sex n (%)**       |                           |                                              |                     |
| Male                | 137 (50.6)                | 134 (49.4)                                   | 1.00                |
| Female              | 60 (46.5)                 | 69 (53.5)                                    | 1.39 (0.82, 2.35)   |
| **Ethnicity, n (%)**|                           |                                              |                     |
| White British/Irish/Other | 98 (47.1)  | 110 (52.9)                                   | 1.00                |
| Any other ethnicity | 99 (51.6)                 | 93 (48.4)                                    | 0.90 (0.53, 1.53)   |
| **Region, n (%)**   |                           |                                              |                     |
| England             | 167 (49.6)                | 170 (50.4)                                   | 1.00                |
| Devolved nations of the UK: Northern Ireland, Scotland, Wales | 30 (47.6) | 33 (52.4)                                   | 1.19 (0.59, 2.44)   |
| **Age, Mean (SD)**  |                           |                                              |                     |
| Years (Continuous)  | 42.2 (9.5)                | 44.4 (10.5)                                  | 0.95 (0.86, 1.04)   |
| **Number of years qualified, Mean (SD)** |             |                                              |                     |
| Years (Continuous)  | 18.1 (10.1)               | 21.1 (10.9)                                  | 1.07 (0.98, 1.17)   |
| **COM-B factors, Mean (SD)** |                   |                                              |                     |
| Capability (4 – 20) | 10.0 (3.2)                | 13.7 (2.8)                                   | 1.39 (1.26, 1.52)** |
| Opportunity (1 – 5) | 2.4 (1.0)                 | 3.2 (1.0)                                    | 1.44 (1.11, 1.87)** |
| Motivation (1 – 5)  | 3.4 (1.0)                 | 4.1 (0.8)                                    | 1.45 (1.05, 2.00)*  |

*R2 = 0.41*

* $P < 0.05$

** $P < 0.05$

*** $P < 0.01$
Discussions

Statement of principal findings
This study found that most CPs encourage patients to spot and respond to potential signs and symptoms of cancer, while less than half help people to make an informed decision to take part in bowel cancer screening. This study also found that all three components of the COM-B model (i.e., Capability, Opportunity, and Motivation) are linked to helping patients make an informed decision about taking part in bowel cancer screening, while only Opportunity and Motivation are linked with encouraging patients to spot and respond to potential signs and symptoms of cancer. Importantly, our study identified specific demographic groups who are more frequently engaged with these behaviours, meaning that we are able to make recommendations about not only the psychological variables that interventions seeking to change behaviour should target, but the populations they could be targeted towards as well. Finally, our study highlighted that, while the demographic and psychological variables examined accounted for a large amount of the variation in CPs’ behaviour (i.e., 34–41%), it does not account for all of the variance. This indicates that there are other important factors that need to be considered and explored in future research.

The meaning of the study: possible explanations and implications for clinicians and policymakers
Previous studies have suggested that further training may increase the confidence of CPs in helping patients to recognise signs and symptoms of cancer [20–22], but have lacked detail on how to achieve this. The present study suggests that a broad approach, targeting both Motivation and Opportunity, specifically, is required. Furthermore, the findings of this study highlight the specific aspects of these components that could be targeted to change behaviour. For example, as shown in Table 1, targeting a CP’s perception of their professional role and identity would be one possible target for intervention development in relation to improving Motivation. The next logical step for policy makers would be to map these psychological targets onto the Behaviour Change Wheel / Behaviour Change Technique Taxonomy, to identify behaviour change techniques that are likely to be effective at modifying these psychological targets and, therefore, CP behaviour [15].

Previous research has also suggested that conversations about cancer screening are a less familiar behaviour to CPs, compared to educating patients about symptom recognition, and one which is usually initiated by the patient [23]. For example, a previous survey study found that 15% of CPs stated that their confidence to discuss bowel cancer screening was ‘poor’ or ‘very poor’, and that only half were aware that bowel cancer screening was for people who did not have symptoms [20]. The present research builds on these findings, by highlighting that it is not just Capability which is important (both of which come under the ‘Capability construct of COM-B), but factors related to Opportunity and Motivation as well (as well as several other factors related to Capability). The need to target all three components of the COM-B model suggests that a more holistic and rounded approach is required to facilitate behaviour change in this context. Indeed, if screening is to become part of a regular conversation initiated by CPs, it may need to be embedded within a pathway, or made part of public health promotional campaigns. One possible strategy would be to inform CPs of patient’s screening outcomes; another would be to streamline processes to enable CPs to request a replacement screening kit for their patients, or for them to be supplied with leaflets by the NHS, which can then be used to facilitate conversations with patients (as well as taken away by patients to provide information, aid memory and facilitate behaviour change).

Strengths and weaknesses of the study
This study had several strengths. First, it contained a diverse range of CPs from different ethnic backgrounds and levels of experience, making the findings more generalisable to the UK CP population (National data suggest 44.8% of CPs are of White British/Irish/Other ethnicity) [17]. Second, it used a forced choice design, meaning that there were no missing data for any of the participants. Third, several quality control measures were implemented, including checking of open-ended responses for completeness (e.g., age, number of years qualified), as well as the time spent on each question, with several cases consequently removed (e.g., speeders). Fourth, the study was grounded in theory, making use of the COM-B Model, allowing for the development of theory-based interventions via the Behaviour Change Wheel. Fifth, the study included a wide range of demographic and psychological variables, and explained a large amount of the variance in CPs’ cancer-related behaviours. Finally, the study used factor analysis to test the validity of the COM-B components, and found high construct validity for the three components, allowing greater confidence to be placed in the trustworthiness of the results.

This study also had several limitations. First, it used self-reported measures for behaviour and may, therefore, be subject to self-report bias, with CPs potentially self-reporting higher frequencies of desired behaviours than practiced (e.g., due to expectations that Pharmacists provide additional healthy living services, as per their contractual framework). Second, this study used
a self-selected sample (only 5% of invited CPs [400 of 8,000] completed the questionnaire), and may, in addition, be subject to self-selection bias, with participating CPs being more engaged with health promotion activities than the general population of CPs (although it is important to note that CPs were not informed the questionnaire was related to cancer, or health promotion [just health] and the demographics of our sample broadly reflect those of the wider CP population in terms of age, sex and ethnicity [the mean age of our sample was 43 years, while that of the wider CP population is 41; 68% of our sample were male, while 62% of the wider population are male; 52% of our sample identified as being a White ethnic background, while 46% of the wider population identify as being of a White ethnic background] [17]) [24]. Third this study used cross-sectional data, as opposed to longitudinal data and, as such, it was not possible to assess how CP cancer-related behaviours have changed over time (it is possible, for example, that during flu season, there is less time for CPs to engage in cancer-related discussions with patients). Fourth, only a small number of CPs from the devolved nations and some ethnic groups participated in the study. As such, there was low power to assess regional and ethnic group differences in behaviour. Fifth, as data on the individual pharmacy CPs were registered with were not collected, it is not possible to say whether the 400 CPs participating in this study were registered with 400 different pharmacies. This may further reduce the representativeness of the sample and the generalisability of its findings. Finally, the survey lacked more quantifiable data on how many patients report to their CPs with cancer-related queries, which would help enable more accurate estimates about the potential benefit and cost effectiveness of training CPs.

**Unanswered questions and future research**

This study highlights several areas for future research. First, future research is needed to understand why female CPs are more likely to encourage patients to spot and respond to potential signs and symptoms of cancer than male CPs. Second, further research is needed to identify additional factors that affect whether CPs engage in these behaviours (the variables included in our study only accounted for 34–41% of the variance in CPs behaviour). It may be, for example, that community pharmacies that see smaller numbers of patients on a daily basis are able to engage in cancer-related conversations more frequently. Third, additional data on the patient-reported experience of CP-led cancer-related consultations is needed to determine whether there are areas for improvement. Finally, future research is needed to explore the role and behaviours of other community pharmacy staff, such as Healthcare Assistants, to understand what role they may play in initiating cancer screening-related conversations with patients in the community pharmacy setting.

**Conclusions**

This study demonstrates that most CPs encourage patients to recognise and respond to potential signs and symptoms of cancer, but that less than half help people to make an informed decision to take part in bowel cancer screening. As such, the results of this study highlight an emerging gap where CPs could play a larger role in helping people to make an informed decision about taking part in bowel cancer screening (one which might be even greater than this study suggests, given the likelihood of self-selection bias by CPs who are more interested in engaging with health promotion activities). The findings from this work suggest that holistic approaches to changing CP behaviours are required to achieve behaviour change, with multiple components of the COM-B model of behaviour being significant predictors of cancer-related working behaviours.

**Abbreviations**

aOR: Adjusted Odds Ratio; CI: Confidence Interval; CP: Community Pharmacist; CRC: Colorectal Cancer; GP: General Practitioner; HPTS: Healthcare Professional Tracker Survey; NHS: National Health Service; SD: Standard Deviation.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12913-022-07587-1.

- Additional file 1.
- Additional file 2.
- Additional file 3.
- Additional file 4.

**Acknowledgements**

The authors would like to thank the community pharmacists for their participation in this study.

**Authors’ contributions**

RK, AR, HS, GK, AK, LM, CI-W, AT, SL, MA, MG, CVW contributed to the design of the project. RK, AR, HS, GK and CW performed the statistical analysis. All authors have seen and approved the final version of the article for publication.

**Funding**

The questionnaire and data collection was funded by Cancer Research UK. Robert Kerrison is supported by a Cancer Research UK Population Research Fellowship [C68512/A28209]. Charlotte Ide-Walters and Lindsay MacDonald are both employed full-time by Cancer Research UK.

**Availability of data and materials**

The data used in this study are available from Open Science Framework: https://osf.io/qutwr/
Declarations

Ethics approval and consent to participate
The study was performed as part of the HPTS. Completion of the Health Research Authority Decision Tool indicated that NHS Research Ethics Committee Review was not required (Appendix 3). All data were anonymous and participants provided informed consent through completion and return of the questionnaire (the purpose of the research was explained prior to data collection). The study was carried out in accordance Market Research Society Code of Conduct, Good Clinical Practice guidelines and the principles set forth in the Declaration of Helsinki.

Competing interests
The authors have no conflicts of interest to declare.

Author details
1. School of Health Sciences, University of Surrey, Surrey, UK. 2. School of Pharmacy, Newcastle University, Newcastle, UK. 3. Acaster Lloyd Consulting Ltd, London, UK. 4. Department of Behavioural Science and Health, University College London, London, UK. 5. Cancer Intelligence Team, Cancer Research UK, London, UK. 6. School of Human Sciences, University of Greenwich, London, UK. 7. Middlesex Group of Local Pharmaceutical Committees, London, UK.

Received: 31 August 2021 Accepted: 6 January 2022
Published online: 28 February 2022

References
1. Cancer Research UK. Cancer Mortality for all cancers combined. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/mortality/all-cancers-combined#heading-Zero (Accessed: 16/04/2021)
2. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève JJTL. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75.
3. Quaife S, Forbes LJ, Ramirez A, Brain K, Donnelly C, Simon A. Wardle JJBjoc: Recognition of cancer warning signs and anticipated delay in help-seeking in a population sample of adults in the UK. Brit J Cancer. 2014;110(1):12–8.
4. Moffat J, Bentley A, Ironmonger L, Boughey A, Radford G, Duffy SJBjoc: The impact of national cancer awareness campaigns for bowel and lung cancer symptoms on sociodemographic inequalities in immediate key symptom awareness and GP attendances. Brit J Cancer. 2015;112(1):514–21.
5. Mitchell E, Macdonald S, Campbell N, Weller D. Macleod UJJboc: Influences on pre-hospital delay in the diagnosis of colorectal cancer: a systematic review. Brit J Cancer. 2008;99(1):60–70.
6. Robb K, Stubbings S, Ramirez A, Macleod U, Austoker J, Waller J, Hiom S, Wardle JNP. Public awareness of cancer in Britain: a population-based survey of adults. Nat Prev. 2009;101:518-523.
7. Hirst Y, Stoffel S, Baig G, McGregor L, von Wagner CJ,JoC. Uptake of the English Bowel (Colorectal) Cancer Screening Programme: an update 5 years after the full roll-out. Eur J Cancer. 2018;103:267–73.
8. NHS England. The NHS Long Term Plan. Available from: https://www.longtermplan.nhs.uk/publication/nhs-long-term-plan/ (Accessed: 16/04/2021)
9. Prentice A, Marshall S, Vance M, Chogley S, Von Wagner C, Kerrison RJJTP. Colorectal cancer screening and the role of community pharmacy. Pharm J. 2019;302(7921):1-11.
10. Todd A, Copeland A, Husband A, Kasim A, Bambara CJ. The pharmacy post-cancer care area-level analysis of the relationship between community pharmacy distribution, urbanity and social deprivation in England. BMJ Open. 2014;4(8):e005764.
11. Lindsey L, Husband A, Steed L, Walton R. Todd A JJoph: Helpful advice and hidden expertise: pharmacy users' experiences of community pharmacy accessibility. J Public Health. 2017;39(3):609–15.
12. Dynata. About Us. Available from: https://www.dynata.com (Accessed: 16/04/2021)
13. Wilmington Healthcare. About Us. Available from: https://wilmingtonhealthcare.com (Accessed: 16/04/2021)
14. Michie S, Atkins L, West RIGBSP. The behaviour change wheel: a guide to designing interventions. 2014. 2015.
15. Michie S, Van Stralen MM, West RJ. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6(1):1–12.
16. Conrad FG, Couper MP, Tournageau R, Zhang C. Reducing speeding in web surveys by providing immediate feedback. Survey Research Meth‑ods. 2017;11(1):45 (NIH Public Access).
17. Wilkinson EJJTP. Asian and Black pharmacists overrepresented in fitness‑to‑practice concerns, GPhC data show. Pharm J. 2018;301(7917):135.
18. Polit DF, Beck CT, Hungler BP. Essentials of Nursing Research Methods, Appraisal and Utilization. 5th ed. Philadelphia: Lippincott; 2001.
19. Rogers F, Richarme MJDA, Inc White Papers. The honesty of online survey respondents: Lessons learned and prescriptive remedies. Decision Ana‑lyst. 2016;800:1–8.
20. Sendall MC, Ostermann L, Brown C, Mccosker LJP. Health promotion of bowel cancer and breast cancer screening in community pharmacies: Pharmacists' perceptions of their role, knowledge and confidence. Pharmacy Practice. 2018;16(4):1275–285.
21. Jiwa M, Spilsbury K, Duke JJApp. Do pharmacists know which patients with bowel symptoms should seek further medical advice? A survey of pharmacists practicing in community pharmacy in Western Australia. Ann Pharmacother. 2010;44(5):910–7.
22. Jiwa M, Sriram D, Khadaroo Z, Ping-Delfos WJ. Could community pharmacies offer an opportunity to improve outcomes for patients with bowel cancer? Qual Prim Care. 2011;19(2):105–8.
23. Lindsay L, Husband A, Nazar H. Todd AJ:Ce: Promoting the early detection of cancer: a systematic review of community pharmacy‑based education and screening interventions. Cancer Epidemiol. 2015;39(5):673–81.
24. Cameron A. Survey of registered pharmacy professionals 2019. Available from: https://www.pharmacyregulation.org/sites/default/files/docum‑ent/gphc-2019-survey-pharmacy-professionals-main-report-2019.pdf (Accessed: 29/10/2021)

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.